or Try an Advanced Search...

    Technical Analysis for XFOR - X4 Pharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 0.34 -7.50% -0.03
    XFOR closed down 7.5 percent on Wednesday, November 20, 2024, on 1.18 times normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical XFOR trend table...
    Date Alert Name Type % Chg
    Calm After Storm Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Calm After Storm Range Contraction -7.50%
    NR7 Range Contraction -7.50%
    NR7-2 Range Contraction -7.50%
    Narrow Range Bar Range Contraction -7.50%
    Wide Bands Range Expansion -7.50%
    Down 3 Days in a Row Weakness -7.50%
    Older End-of-Day Signals for XFOR ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 16 hours ago
    Down 3% about 16 hours ago
    Fell Below Previous Day's Low about 16 hours ago
    Down 2 % about 16 hours ago
    Down 1% about 16 hours ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    XFOR Chart by TradingView
    Basic chart:

    Profile

    X4 Pharmaceuticals, Inc., formerly Arsanis, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutics for the treatment of rare diseases including primary immunodeficiencies and cancer. The Company’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. Its product candidates include X4P-001, X4P-002 and X4P-003.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Rare Diseases Small Molecule Treatment Of Rare Diseases

    Is XFOR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 20 Spotlight On 3 US Penny Stocks With At Least $60M Market Cap
    Nov 14 XFOR: Positive Results for Phase 2 Trial of Mavorixafor in Chronic Neutropenia…
    Nov 14 X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
    Nov 14 X4 Pharmaceuticals Inc (XFOR) Q3 2024 Earnings Call Highlights: Strategic Engagement and ...
    Nov 14 X4 Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
    Nov 14 X4 Pharmaceuticals, Inc. (XFOR) Q3 2024 Earnings Call Transcript
    Nov 13 X4 Pharmaceuticals: Q3 Earnings Snapshot
    Nov 13 X4 Pharmaceuticals GAAP EPS of -$0.18 misses by $0.01, revenue of $0.56M misses by $1.13M
    Nov 13 X4 Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
    Nov 13 X4 Pharmaceuticals Announces Positive Results from Completed Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN)
    See more XFOR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 1.6
    52 Week Low 0.2616
    Average Volume 2,731,907
    200-Day Moving Average 0.84
    50-Day Moving Average 0.56
    20-Day Moving Average 0.49
    10-Day Moving Average 0.47
    Average True Range 0.07
    RSI (14) 35.90
    ADX 35.15
    +DI 10.91
    -DI 34.26
    Chandelier Exit (Long, 3 ATRs) 0.47
    Chandelier Exit (Short, 3 ATRs) 0.47
    Upper Bollinger Bands 0.69
    Lower Bollinger Band 0.29
    Percent B (%b) 0.12
    BandWidth 81.24
    MACD Line -0.05
    MACD Signal Line -0.03
    MACD Histogram -0.0192
    Fundamentals Value
    Market Cap 56.95 Million
    Num Shares 167 Million
    EPS -0.68
    Price-to-Earnings (P/E) Ratio -0.50
    Price-to-Sales 53.87
    Price-to-Book 2.35
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.42
    Resistance 3 (R3) 0.42 0.39 0.40
    Resistance 2 (R2) 0.39 0.37 0.39 0.40
    Resistance 1 (R1) 0.37 0.36 0.35 0.37 0.39
    Pivot Point 0.34 0.34 0.33 0.34 0.34
    Support 1 (S1) 0.32 0.32 0.30 0.32 0.29
    Support 2 (S2) 0.29 0.31 0.29 0.28
    Support 3 (S3) 0.27 0.29 0.28
    Support 4 (S4) 0.27